Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Chinese Hemodialysis Producer Signs Global Manufacturing Agreement

This article was originally published in PharmAsia News

Executive Summary

China's largest hemodialysis consumables producer Bain Medical Equipment (Guangzhou) has signed a global manufacturing agreement with the world's second largest artificial kidney manufacturer, Japan Asahi Kasei Kuraray Medical. Under the $10 million deal, Bain will provide loop dialysis catheter and puncture needles to the latter. Besides greater profits, Bain believes it will benefit even more from the management experience of the Japanese partner. Medical device manufacturing deals are not easily modified once signed since clinical trials and registration can take as long as two years. Moreover, few domestic enterprises produce moderate- and high-end products for global medical device makers, so the local firm's own brands will also become more internationally competitive. (Click here for more - Chinese Language)

You may also be interested in...

The Quality Lowdown: US FDA Finding New Crop Of Data Integrity Problems

Manufacturers warned to keep better electronic records and not falsify data in recent warning letters, ICH adds three residual solvent limits for pharmaceuticals, and the Polish authority hits firm for GMP noncompliance.

Decision By US COVID-19 Testing Czar To Step Down Critiqued By Key Health Panel Senator

Washington State Sen. Patty Murray said at a 4 June health panel hearing that having USPHS Admiral Brett Giroir step down as the nation’s COVID-19 “Testing Czar” is a bad move, but HHS disagrees.

Pink Sheet Podcast: Merck’s Frazier Speaks Out, US FDA’s Hahn On Decisions, Operation Warp Speed, Worries About User Fee Goal Delays

Pink Sheet reporters and editor discuss Merck CEO Ken Frazier’s thoughts on racial inequity, FDA Commissioner’s explanation of coronavirus decision-making and Operation Warp Speed changes, and consider fears about the potential for user fee goal delays.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts